M RAMAZAN YİĞİTOĞLU, MUSTAFA SOLAK, N KEMAL KUŞÇU, ÇİĞDEM ERESEN, SEMRA ORUÇ, TEVHİDE FISTIK, ZEKİ ARI, FİLİZ PARALI
Kocatepe Tıp Dergisi - 1999;1(1):29-32
The Triple Test which is designed to measure α-Fetoprotein (AFP), human chorionic gonadotropin (HCG), and unconjugated estriol (uE3) levels between 16-18 weeks of gestational age is carried out to screen Down's syndrome among pregnant women. Women with multiple pregnancies and gestational diabetes were not included. About 60-65 % of cases with Down's syndrome can be detected with this method. Using this information and carrying out the test on 70 pregnant patients between 16-18 weeks of gestational age who applied to our clinic for prenatal visit, we found out that Down's syndrome risk was above 1/250 in 16 cases. Fetal karyotype analysis was performed by amniocentesis to 13 (%19) pregnant women. To 3 (%4) high, risk women amniocentesis and cordoccntesis both were carried out. As a result of the chromosome analysis, normal karyotype was detected in 15 (% 94) cases while Down's syndrome (47,XY,+21) was found in 1 (%6) case. Maternal age of the case with Down's syndrome was 23 and the triple test revealed 1/50 risk. According to these preliminary results of our ongoing study, the triple test has been assigned to be an effective screening method for Down's syndrome. Information in detail will be obtained by the end of the study.
